Crossmark

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Crossref DOI link: https://doi.org/10.1186/s12885-020-07710-7

Published Online: 2021-01-05

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Smith-Palmer, J. http://orcid.org/0000-0001-6049-1241
Leeuwenkamp, O. R.

Virk, J.

Reed, N.
Funding

Funding for this research was provided by:

Advanced Accelerator Applications (N/A)
License Information

Text and Data Mining valid from 2021-01-05

Version of Record valid from 2021-01-05
More Information

Article History

Received: 19 January 2020

Accepted: 3 December 2020

First Online: 5 January 2021

Ethics approval and consent to participate

: Not applicable. No new patient data were generated as part of this analysis.

: Not applicable.

: OL and JV are current employees of AAA, which manufactures Lutathera. JSP is a current employee of Ossian Health Economics and Communications, which has received consulting fees from AAA. NR has received honoraria/consulting fees from Novartis/AAA, which manufactures Lutathera as well as Roche, Esai and Ipsen.

Document is current

Any future updates will be listed below